Please Wait.....
Report
Global Biosimilars Business and Investment Opportunities - Analysis and Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update
Market Report I 2023-03-24 I 1350 Pages I BioIntel360
Insights and data in the report have been segmented under the following six modules:
Module 1: Global Biosimilars Funding and Investments Outlook
This module provides insights and data related to biosimilars partnerships and investment (research and development, mergers and acquisitions, product development, commercialization, licensing, and manufacturing) and allows a peek into the futuristic trends of biosimilars technology investment area.
Module 2: Global Biosimilars Clinical Trial Data Assessment
This module evaluates the data available from clinical trials conducted utilising cell and gene technology, representing a bird's eye view of emerging market dynamics and risks in the biosimilars sector.
Module 3: Global Biosimilars Patent Data Analysis
This module presents an exhaustive study of biosimilars patent analytics at various levels, including strategic research planning as well as analyzing their potential applications.
Module 4: Competitive Landscape
This module provides detailed information along with a scoring matrix of key companies related to the biosimilars industry, including their historical performance and the latest developments.
Module 5: Global Biosimilars Market Size and Forecast
This module provides projections on the market's development during the years 2018-2027 after the profound evaluation of market dynamics at the deeper segmentation level. This report also provides an in-depth, data-centric analysis of the global biosimilars market at regional and country levels:
Biosimilar Market Size By Product
- Monoclonal Antibody Biosimilars
- Insulin Biosimilar
- Biosimilar Interferons
- Other Biosimilar
Biosimilar Market Size By Type of Cell
- Mammalian
- Non-Mammalian
Biosimilar Market Size By Imaging Technique
- Magnetic Resonance Imaging Scanners
- Computed Tomography Scanners
- Positron Emission Tomography Scanners
- Others
Biosimilar Market Size By Procedure
- Invasive
- Non-Invasive
Biosimilar Market Size By Source of Manufacturing
- In-House
- Contract Manufacturing
Biosimilar Market Size By Applications
- Oncology
- Blood Disorders
- Growth Hormonal Deficiency
- Chronic & Autoimmune Disorders
- Infectious Diseases
- Others
Biosimilar Market Size By Type of Technology
- Mass Spectroscopy
- Chromatography
- Recombinant DNA technology
- Electrophoresis
- Others
Biosimilar Market Size By End User
- Hospital & Clinics
- Diagnostic Centres
- Others
Biosimilar Market Size By Regions
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Germany
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- Australia
- India
- South Korea
- MEA region
- Israel
- South Africa
- Turkey
- Saudi Arabia
- Latin America
- Brazil
- Argentina
- Colombia
Key Companies Covered
- Amgen Inc
- Novartis
- Eli Lilly and Company
- Celltrion Inc
- Dr. Reddy's Laboratories Ltd
- Fresenius SE & Co. KGAA
- Samsung Biologics
- Biocon Limited
Module 6 Regulatory Outlook
This module contains a detailed understanding of the ethical, legal, and social implications of biosimilars.
This market intelligence report features an in-depth analysis on the current market dynamics of the biosimilars market.
It provides a detailed analysis of biosimilar market dynamics, covering clinical trials, patent data, financial deals, and competitive landscape through 35 sections, 700+ tables, and 1000+ charts.
Chapter 1 About this Report
1.1 Research Methodology
1.2 Definitions
1.3 Disclaimer
Chapter 2 Global Biosimilars Market Outlook and Future Growth Dynamics
2.1 Introduction
2.2 Market Opportunities and Growth Dynamics
2.3 Regulation and Challenges Related to Biosimilars Around the Globe
Chapter 3 Regulatory Dynamics Assessment Across Different regions
3.1 North America Biosimilars Regulations
3.2 Europe Biosimilars Regulations
3.3 Asia Pacific Biosimilars Regulations
3.4 Latin America Biosimilars Regulations
3.5 Middle East & Africa region Biosimilars Regulation
Chapter 4 Discovery and Clinical Pipeline Market Attractiveness
4.1 Biosimilars Based: Discovery and Clinical Pipeline
4.2 FDA Approved Biosimilars, 2017-2022
4.3 EMEA Approved Biosimilars, 2017-2022
4.4 List of Top 10 Innovation Driving Worldwide Biologics Sales in 2022
4.5 List of Biologics Coming Off Patents Between 2023 to 2027
Chapter 5 Global Biosimilars Financial Deals & Alliances Market Dynamics & Outlook
5.1 Biosimilars Financial Deals & Alliances Market Prediction and Estimation
5.2 Biosimilars Financial Deals Vs Mergers & Acquisition, 2022 vs 2025
5.3 Biosimilars Financial Deals Analysis by Type of Cell, 2022 vs 2025
5.4 Biosimilars Financial Deals Analysis by Therapeutic Class, 2022 vs 2025
5.5 Biosimilars Financial Deals Analysis by Phase-Wise Deals, 2022 vs 2025
5.6 Biosimilars Financial Deals Analysis by Type of Procedure, 2022 vs 2025
5.7 Biosimilars Financial Deals Analysis by Type of Industry, 2022 vs 2025
5.8 Biosimilars Financial Deals Analysis by Region, 2022 vs 2025
5.9 Biosimilars Fundings and Investment Analysis by Funding Type, 2018-2022
5.10 Biosimilars Fundings and Investment Analysis by Funding Stage, 2018-2022
5.11 Recent Deals and Partnerships of Biosimilars
5.12 Recent Biosimilars Mergers and Acquisitions
5.13 Global Biosimilars Deals Landscape, 2022
Chapter 6 Biosimilars Patent Analysis & Outlook
6.1 Biosimilars Historical and Futuristic Trend of Patent, 2018-2027
6.2 Biosimilars Patent Analysis by Type of Players, 2022 vs 2025
6.3 Biosimilars Patent Analysis by Patent Type, 2018-2022
6.4 Biosimilars Patent Analysis by Legal Status, 2018-2022
6.5 Biosimilars Patent Analysis by Top Patent Owners
6.6 Biosimilars Patent Analysis by Top Patent Applicants
6.7 Biosimilars: Biosimilars Top Patent Applicants Benchmarking Analysis
6.8 Biosimilars Patent Analysis by Published Status
6.9 Biosimilars Patent Analysis by Investors
6.10 Biosimilars Patent Analysis by CPC Classification Code
6.11 Biosimilars Patent Documents by Jurisdiction
6.12 Biosimilars Company Patent Filing Analysis
6.13 List of Recent Biosimilars Patents
Chapter 7 Biosimilars Clinical Trial Analysis & Outlook
7.1 Biosimilars Clinical Trial Historical and Futuristics Trend
7.2 Biosimilars Clinical Trial Region-wise Prediction & Estimation, 2018-2027
7.3 Biosimilars Clinical Trial Analysis by Country-wise Analysis
7.4 Biosimilars Clinical Trial Analysis by Age Group
7.5 Biosimilars Clinical Trial Analysis by Funding Agency
7.6 Biosimilars Clinical Trial Analysis by Documents
7.7 Biosimilars Clinical Trial Analysis by Diseases-wise
7.8 Biosimilars Clinical Trial Analysis by Phase-wise
7.9 Biosimilars Clinical Trial Analysis by Status
7.10 Biosimilars Clinical Trial Analysis by Study Type
7.11 Biosimilars Clinical Trial Analysis by Type of Rare Diseases
Chapter 8 Biosimilars Competitive Landscape Analysis: Key Company Profiles and Strategic Initiatives
8.1 Biosimilars Competitive Index Ranking & Attractiveness Quadrant
8.2 Biosimilars Company Market Share
8.3 Biosimilars Competitive Mapping Quadrant
8.4 Biosimilars Competitive Landscape by Count of Biosimilar
8.5 Count of Biosimilar Company by Approval Year
8.6 Biosimilars Competitive Landscape by Region
8.7 Key Companies by Regions
8.8 Biosimilar Company Clinical Pipeline Count
8.9 Count of Biosimilar by Therapeutics Area
8.10 Biosimilars Developers Worldwide
8.11 Amgen Inc
8.12 Novartis
8.13 Eli Lilly and Company
8.14 Celltrion Inc
8.15 Dr. Reddy's Laboratories Ltd
8.16 Fresenius SE & Co. KGAA
8.17 Samsung Biologics
8.18 Biocon Limited
Chapter 9 Global Biosimilar Market Size and Forecast, 2018-2027
9.1 Global Biosimilar Market Size and Forecast, 2018-2027
9.2 Global Biosimilar Market Share by Product, 2018-2027
9.2.1 Biosimilar Market Size by Monoclonal Antibody Biosimilars, 2018-2027
9.2.2 Biosimilar Market Size by Insulin Biosimilar, 2018-2027
9.2.3 Biosimilar Market Size by Biosimilar Interferons, 2018-2027
9.2.4 Biosimilar Market Size by Other Biosimilars, 2018-2027
9.3 Global Biosimilar Market Share by Monoclonal Antibody Biosimilars, 2018-2027
9.4 Biosimilar Market Share by Insulin Biosimilars, 2018-2027
9.5 Biosimilar Market Share by Interferons Biosimilars, 2018-2027
9.6 Biosimilar Market Share by Other Biosimilars, 2018-2027
9.7 Global Biosimilar Market Share by Type of Cell, 2018-2027
9.7.1 Biosimilar Market Size by Mammalian Cell, 2018-2027
9.7.2 Biosimilar Market Size by Non-Mammalian Cell, 2018-2027
9.8 Global Biosimilar Market Share by Imaging Technique, 2018-2027
9.8.1 Biosimilar Market Size by Magnetic Resonance Imaging Scanners, 2018-2027
9.8.2 Biosimilar Market Size by Computed Tomography Scanners, 2018-2027
9.8.3 Biosimilar Market Size by Positron Emission Tomography Scanners, 2018-2027
9.8.4 Biosimilar Market Size by Others, 2018-2027
9.9 Global Biosimilar Market Share by Procedure, 2018-2027
9.9.1 Biosimilar Market Size by Invasive Procedure, 2018-2027
9.9.2 Biosimilar Market Size by Non-Invasive Procedure, 2018-2027
9.10 Global Biosimilar Market Share by Source of Manufacturing, 2018-2027
9.10.1 Biosimilar Market Size by In-House, 2018-2027
9.10.2 Biosimilar Market Size by Contract Manufacturing, 2018-2027
9.11 Global Biosimilar Market Share by Applications, 2018-2027
9.11.1 Biosimilar Market Size by Oncology, 2018-2027
9.11.2 Biosimilar Market Size by Blood Disorders, 2018-2027
9.11.3 Biosimilar Market Size by Growth Hormonal Deficiency, 2018-2027
9.11.4 Biosimilar Market Size by Chronic & Autoimmune Disorders, 2018-2027
9.11.5 Biosimilar Market Size by Infectious Diseases, 2018-2027
9.11.6 Biosimilar Market Size by Others, 2018-2027
9.12 Global Biosimilar Market Share by Type of Technology, 2018-2027
9.12.1 Biosimilar Market Size by Mass Spectroscopy, 2018-2027
9.12.2 Biosimilar Market Size by Chromatography, 2018-2027
9.12.3 Biosimilar Market Size by Recombinant DNA Technology, 2018-2027
9.12.4 Biosimilar Market Size by Electrophoresis, 2018-2027
9.12.5 Biosimilar Market Size by Others, 2018-2027
9.13 Global Biosimilar Market Share by End User, 2018-2027
9.13.1 Biosimilar Market Size by Hospital & Clinics, 2018-2027
9.13.2 Biosimilar Market Size by Diagnostic Centres, 2018-2027
9.13.3 Biosimilar Market Size by Others, 2018-2027
Chapter 10 - Chapter 35: This section contains chapters providing biosimilar market sizing and forecast for additional 20 countries and 5 regions.
This report includes 700+ tables across various sections covering global, regional, and country level analysis. Due to space constraints, limited number of tables have been displayed here.
Table 1: Biosimilars Financial Deals Market Size and Forecast, by Value (USD Million), 2018-2027
Table 2: Biosimilars Financial Deals Market Size and Forecast, by Volume, 2018-2027
Table 3: Global Biosimilar Market Size by Value (USD MM) 2018-2027
Table 4: Global Biosimilar Market Size by Monoclonal Antibody Biosimilars, by Value (USD MM), 2018-2027
Table 5: Global Biosimilar Market Size by Insulin Biosimilar, by Value (USD MM) 2018-2027
Table 6: Global Biosimilar Market Size by Biosimilar Interferons, by Value (USD MM) 2018-2027
Table 7: Global Biosimilar Market Size by Other Biosimilars, by Value (USD MM) 2018-2027
Table 8: Global Biosimilar Market Size by Mammalian Cell, by Value (UDS MM) 2018-2027
Table 9: Global Biosimilar Market Size by Non-Mammalian Cell, by Value (UDS MM) 2018-2027
Table 10: Global Biosimilar Market Size by Magnetic Resonance Imaging Scanners, by Value (USD MM), 2018-2027
Table 11: Global Biosimilar Market Size by Computed Tomography Scanners, by Value (USD MM), 2018-2027
Table 12: Global Biosimilar Market Size by Positron Emission Tomography Scanners, by Value (USD MM), 2018-2027
Table 13: Global Biosimilar Market Size by Others, by Value (USD MM), 2018-2027
Table 14: Global Biosimilar Market Size by Invasive Procedure (USD MM), 2018-2027
Table 15: Global Biosimilar Market Size by Non-Invasive Procedure (USD MM), 2018-2027
Table 16: Global Biosimilar Market Size by In-House, by Value (USD MM), 2018-2027
Table 17: Global Biosimilar Market Size by Contract Manufacturing, by Value (USD MM), 2018-2027
Table 18: Global Biosimilar Market Size by Oncology, by Value (USD MM), 2018-2027
Table 19: Global Biosimilar Market Size by Blood Disorders, by Value (USD MM), 2018-2027
Table 20: Global Biosimilar Market Size by Growth Hormonal Deficiency, by Value (USD MM), 2018-2027
Table 21: Global Biosimilar Market Size by Chronic & Autoimmune Disorders, by Value (USD MM), 2018-2027
Table 22: Global Biosimilar Market Size by Infectious Diseases, by Value (USD MM), 2018-2027
Table 23: Global Biosimilar Market Size by Others, by Value (USD MM), 2018-2027
Table 24: Global Biosimilar Market Size by Mass Spectroscopy, by Value (USD MM), 2018-2027
Table 25: Global Biosimilar Market Size by Chromatography, by Value (USD MM), 2018-2027
Table 26: Global Biosimilar Market Size by Recombinant DNA Technology, by Value (USD MM), 2018-2027
Table 27: Global Biosimilar Market Size by Electrophoresis, by Value (USD MM), 2018-2027
Table 28: Global Biosimilar Market Size by Others, by Value (USD MM), 2018-2027
Table 29: Global Biosimilar Market Size by Hospital & Clinics, by Value (USD MM), 2018-2027
Table 30: Global Biosimilar Market Size by Diagnostic Centres, by Value (USD MM), 2018-2027
Table 31: Global Biosimilar Market Size by Others, by Value (USD MM), 2018-2027
Table 32 - 725: For more information, please contact us on info@biointel360.com
This report includes 1000+ figures across various sections covering global, regional, and country-level analysis. Due to space constraints, a limited number of figures have been displayed here.
Figure 1: BioIntel360 Research Methodology
Figure 2: Biosimilars Important Historical Events
Figure 3: Estimated and Predicted FDA Biosimilar Approvals and Launches by Year
Figure 4: List of FDA Approved Biosimilars, 2017-2022
Figure 5: List of EMEA Approved Biosimilars, 2017-2022 (1/2)
Figure 6: List of Top 10 Innovations Driving Worldwide Biologics Sales in 2022
Figure 7: List of Biologics Coming Off Patents Between 2023 to 2027
Figure 8: Biosimilars Financial Deals & Alliances Market Size and Forecast, by Value (USD Million), 2018-2027
Figure 9: Biosimilars Financial Deals & Alliances Market Share and Forecast, by Volume (%), 2018-2027
Figure 10: Global Biosimilars: Financial Deals Vs Mergers & Acquisition Analysis, 2022 vs 2025
Figure 11: Global Biosimilars Financial Deals: Analysis by Type of Cell, 2022 vs 2025
Figure 12: Global Biosimilars Financial Deals: Analysis by Therapeutic Class, 2022 vs 2025
Figure 13: Global Biosimilars Financial Deals: Analysis by Phase-Wise Deals, 2022 vs 2025
Figure 14: Global Biosimilars Financial Deals: Analysis by Type of Procedure, 2022 vs 2025
Figure 15: Global Biosimilars Financial Deals: Analysis by Type of Industry, 2022 vs 2025
Figure 16: Global Biosimilars Financial Deals: Analysis by Region, 2022 vs 2025
Figure 17: Global Biosimilars Fundings and Investment: Analysis by Funding Type, 2018-2022
Figure 18: Global Biosimilars Fundings and Investment: Analysis by Funding Stage, 2018-2022
Figure 19: Recent Deals and Partnership of Biosimilars
Figure 20: Recent Biosimilars Mergers and Acquisitions
Figure 21: Global Biosimilars Deals (> USD 1 Billion) Landscape, 2022
Figure 22: Biosimilars Historic & Futuristics Trends of Patent, by Volume, 2018-2027
Figure 23: Biosimilars Patent: Analysis by Type of Players, 2022 vs 2025
Figure 24: Biosimilars Patent: Analysis by Patent Type, 2018-2022
Figure 25: Biosimilars Patent: Analysis by Patent Legal Status, 2018-2022
Figure 26: Biosimilars Patent: Analysis by Top Patent Owners, 2022
Figure 27: Biosimilars Patent: Analysis by Top Patent Applicants, 2022
Figure 28: Biosimilars Key Patent Applicant: Iovance Biotherapeutics INC and CPC Classification Code Analysis, 2022
Figure 29: Biosimilars Key Patent Applicant: Fresenius Kabi Deutschland Gmbh and CPC Classification Code Analysis, 2022
Figure 30: Biosimilars Key Patent Applicant: Bolt Biotherapeutics INC and CPC Classification Code Analysis, 2022
Figure 31: Biosimilars Key Patent Applicant: Janssen Biotech INC and CPC Classification Code Analysis, 2022
Figure 32: Biosimilars Key Patent Applicant: Fate Therapeutics INC and CPC Classification Code Analysis, 2022
Figure 33: Biosimilars Patent: Analysis by Published Status, 2018-2022
Figure 34: Biosimilars Patent: Analysis by Investors, 2022
Figure 35: Biosimilars Patent: Analysis by CPC Classification Code, 2022
Figure 36: Biosimilars Patent: Analysis by Documents by Jurisdiction, 2022
Figure 37: Biosimilars Company Patent Filing Analysis
Figure 38: List of Recent Biosimilars Patents
Figure 39: Biosimilars Clinical Trial Historical and Futuristics Trend, by Volume, 2018-2027
Figure 40: Biosimilars Clinical Trial Region-wise Share and Forecast, by Volume (%), 2018-2027
Figure 41: Biosimilars Clinical Trial: Analysis by Country-wise
Figure 42: Biosimilars Clinical Trial: Analysis by Age Group
Figure 43: Biosimilars Clinical Trial: Analysis by Funding Agency
Figure 44: Biosimilars Clinical Trial: Analysis by Documents
Figure 45: Biosimilars Clinical Trial: Analysis by Diseases-wise, by Volume
Figure 46: Biosimilars Clinical Trial: Analysis by Phase-wise
Figure 47: Biosimilars Clinical Trial: Analysis by Status
Figure 48: Biosimilars Clinical Trial: Analysis by Study Type
Figure 49: Share of Biosimilars in Pipeline Targeting Rare Diseases
Figure 50: Biosimilars Companies Competitive Landscape
Figure 51: Biosimilars: Companies by Market Share, 2022
Figure 52: Biosimilars Companies Mapping Quadrant
Figure 53: Count of Biosimilars by Companies
Figure 54: Count of Biosimilars by Companies
Figure 55: Biosimilars Company by Regional Analysis
Figure 56: Biosimilars: Companies by Geography
Figure 57: Biosimilar Company Clinical Pipeline Count
Figure 58: Count of Biosimilars by Therapeutics Area
Figure 59: Number of Biosimilars Developers Worldwide
Figure 60: Global Biosimilar Market Size by Value (USD MM) 2018-2027
Figure 61: Global Biosimilar Market Share by Product (%), 2018-2027
Figure 62: Global Biosimilar Market Size by Monoclonal Antibody Biosimilars, by Value (USD MM), 2018-2027
Figure 63: Global Biosimilar Market Size by Insulin Biosimilar, by Value (USD MM) 2018-2027
Figure 64: Global Biosimilar Market Size by Biosimilar Interferons, by Value (USD MM) 2018-2027
Figure 65: Global Biosimilar Market Size by Other Biosimilars, by Value (USD MM) 2018-2027
Figure 66: Global Biosimilar Market Share Monoclonal Antibody Biosimilars (%), 2018-2027
Figure 67: Global Biosimilar Market Share by Insulin Biosimilars (%), 2018-2027
Figure 68: Global Biosimilar Market Share by Interferons Biosimilars (%), 2018-2027
Figure 69: Global Biosimilar Market Share by Other Biosimilars (%), 2018-2027
Figure 70: Global Biosimilar Market Share by Type of Cell (%), 2018-2027
Figure 71: Global Biosimilar Market Share by Mammalian Cell, by Value (UDS MM) 2018-2027
Figure 72: Global Biosimilar Market Share by Non-Mammalian Cell, by Value (UDS MM) 2018-2027
Figure 73: Global Biosimilar Market Share by Imaging Technique (%), 2018-2027
Figure 74: Global Biosimilar Market Size by Magnetic Resonance Imaging Scanners, by Value (USD MM), 2018-2027
Figure 75: Global Biosimilar Market Size by Computed Tomography Scanners, by Value (USD MM), 2018-2027
Figure 76: Global Biosimilar Market Size by Positron Emission Tomography Scanners, by Value (USD MM), 2018-2027
Figure 77: Global Biosimilar Market Size by Others, by Value (USD MM), 2018-2027
Figure 78: Global Biosimilar Market Share by Procedure (%), 2018-2027
Figure 79: Global Biosimilar Market Size by Invasive Procedure (USD MM), 2018-2027
Figure 80: Global Biosimilar Market Size by Non-Invasive Procedure (USD MM), 2018-2027
Figure 81: Global Biosimilar Market Share by Source of Manufacturing (%), 2018-2027
Figure 82: Global Biosimilar Market Size by In-House, by Value (USD MM), 2018-2027
Figure 83: Global Biosimilar Market Size by Contract Manufacturing, by Value (USD MM), 2018-2027
Figure 84: Global Biosimilar Market Share by Applications (%), 2018-2027
Figure 85: Global Biosimilar Market Size by Oncology, by Value (USD MM), 2018-2027
Figure 86: Global Biosimilar Market Size by Blood Disorders, by Value (USD MM), 2018-2027
Figure 87: Global Biosimilar Market Size by Growth Hormonal Deficiency, by Value (USD MM), 2018-2027
Figure 88: Global Biosimilar Market Size by Chronic & Autoimmune Disorders, by Value (USD MM), 2018-2027
Figure 89: Global Biosimilar Market Size by Infectious Diseases, by Value (USD MM), 2018-2027
Figure 90: Global Biosimilar Market Size by Others, by Value (USD MM), 2018-2027
Figure 91: Global Biosimilar Market Share by Type of Technology (%), 2018-2027
Figure 92: Global Biosimilar Market Size by Mass Spectroscopy, by Value (USD MM), 2018-2027
Figure 93: Global Biosimilar Market Size by Chromatography, by Value (USD MM), 2018-2027
Figure 94: Global Biosimilar Market Size by Recombinant DNA Technology, by Value (USD MM), 2018-2027
Figure 95: Global Biosimilar Market Size by Electrophoresis, by Value (USD MM), 2018-2027
Figure 96: Global Biosimilar Market Size by Others, by Value (USD MM), 2018-2027
Figure 97: Global Biosimilar Market Share by End User (%), 2018-2027
Figure 98: Global Biosimilar Market Size by Hospital & Clinics, by Value (USD MM), 2018-2027
Figure 99: Global Biosimilar Market Size by Diagnostic Centres, by Value (USD MM), 2018-2027
Figure 100: Global Biosimilar Market Size by Others, by Value (USD MM), 2018-2027
Figure 101 - 1125: For more information, please contact us on info@biointel360.com
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security